KURE in “China Becomes Pharma's Global R&D Engine”
KraneShares MSCI All China Health Care Index ETF
KURE provides diversified exposure to Chinese biotechnology, pharmaceutical, hospital and healthcare companies that could benefit from rising global demand for China-origin drug assets.
KURE impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to KURE’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading KURE impact map…
Price history, marked with story events
Feb 1, 2021 – Feb 2, 2022 · 255 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — KURE provides diversified exposure to Chinese biotechnology, pharmaceutical, hospital and healthcare companies that could benefit from rising global demand for China-origin drug assets.
Read the full China Becomes Pharma's Global R&D Engine story